Roche Holding AG reported disappointing revenue for a blockbuster eye medicine and lackluster growth predictions for the year.
The shares fell in early trading after the Swiss drugmaker said Bloomberg Terminalsales of the ophthalmology treatment only rose 7% last quarter amid a slowdown in the US. Roche also issued the same cautious profit and sales forecast as last year, which may prompt some analysts to revise their estimatesBloomberg Terminal.